suggests the Moderna vaccine’s advantage in terms of long-term protection. In multiple independent studies, significantly lower antibody levels and more vaccine breakthrough infections have been ...

Moderna said Friday that the European Patent Office has upheld the validity of one of its key patents, a victory in a continuing dispute with Pfizer and BioNTech over rival COVID-19 vaccines.

US pharmaceutical company Moderna Friday sued Pfizer / BioNTech over patent ownership infringement regarding the COVID-19 RNA vaccine “Moderna is convinced that Pfizer and BioNTech's Comirnaty ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines ... and competing technologies could prove safer and more effective.

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent dispute centring on their mRNA-based vaccines for COVID-19. Moderna fired the first volley back in August ...

For Pfizer's and Moderna's two-shot vaccines, the second shot amplifies an existing immune response, so people typically feel more run-down after that dose. Vaccines prompt our bodies to produce ...

Covid vaccines from companies like Pfizer, Moderna and AstraZeneca were linked ... (COVID-19), so getting vaccinated is still ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Top vaccine stocks for investors to consider include Pfizer and Moderna. Other vaccine stocks to watch include Bavarian Nordic and Emergent BioSolutions. Key findings are powered by ChatGPT and ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...